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A bs tr ac t
Background
Current treatment recommendations for patients with polycythemia vera call for 
maintaining a hematocrit of less than 45%, but this therapeutic strategy has not 
been tested in a randomized clinical trial.
Methods
We randomly assigned 365 adults with JAK2-positive polycythemia vera who were 
being treated with phlebotomy, hydroxyurea, or both to receive either more inten-
sive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treat-
ment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite 
end point was the time until death from cardiovascular causes or major thrombotic 
events. The secondary end points were cardiovascular events, cardiovascular hospital-
izations, incidence of cancer, progression to myelofibrosis, myelodysplasia or leuke-
mic transformation, and hemorrhage. An intention-to-treat analysis was performed.
Results
After a median follow-up of 31 months, the primary end point was recorded in 5 of 
182 patients in the low-hematocrit group (2.7%) and 18 of 183 patients in the high-
hematocrit group (9.8%) (hazard ratio in the high-hematocrit group, 3.91; 95% 
confidence interval [CI], 1.45 to 10.53; P = 0.007). The primary end point plus super-
ficial-vein thrombosis occurred in 4.4% of patients in the low-hematocrit group, as 
compared with 10.9% in the high-hematocrit group (hazard ratio, 2.69; 95% CI, 
1.19 to 6.12; P = 0.02). Progression to myelofibrosis, myelodysplasia or leukemic 
transformation, and bleeding were observed in 6, 2, and 2 patients, respectively, in 
the low-hematocrit group, as compared with 2, 1, and 5 patients, respectively, in the 
high-hematocrit group. There was no significant between-group difference in the 
rate of adverse events.
Conclusions
In patients with polycythemia vera, those with a hematocrit target of less than 45% 
had a significantly lower rate of cardiovascular death and major thrombosis than 
did those with a hematocrit target of 45 to 50%. (Funded by the Italian Medicines 
Agency and others; ClinicalTrials.gov number, NCT01645124, and EudraCT number, 
2007–006694-91.)
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Polycythemia vera is a rare hemato-logic neoplasm characterized by clonal proliferation of multipotent bone marrow 
progenitors, leading to abnormal production of 
erythroid cells and an increased red-cell mass.1-4 
Acquired mutations in JAK2 (JAK2 V617F and 
exon 12 mutations) are found in almost all pa-
tients with polycythemia vera.5,6 Major causes of 
death and complications include thrombosis, 
bleeding, and hematologic transformation into 
overt myelofibrosis or acute leukemia.
Recommendations for the management of 
polycythemia vera are based on thrombotic risk 
and a limited number of randomized clinical 
trials and observational studies that described 
the clinical course of the disease and indirectly 
evaluated the role of different treatments. Thus, 
evidence from prospective clinical trials is lim-
ited, and clinical expertise still plays a major 
role in guiding therapy in patients with this 
disease. It is recommended that the hematocrit 
be kept below 45% and the platelet count below 
400,000 per cubic millimeter on the basis of 
studies1,4 that showed a proportional increase in 
the rate of thrombotic events with increased 
hematocrits and platelet counts. Intensive man-
agement of these hematologic variables is widely 
practiced, despite the lack of solid data in sup-
port of this recommendation.4 Indeed, a post 
hoc analysis of two large, randomized clinical 
trials7-9 did not show a significant increase in 
the incidence of major thrombosis when a hema-
tocrit of 45 to 50% was maintained. Thus, the 
usefulness of tight hematocrit control in reduc-
ing thrombosis is uncertain, and an aggressive 
treatment to reach that hematocrit target could 
result in toxic effects.
In a large-scale, multicenter, prospective, ran-
domized clinical trial, called the Cytoreductive 
Therapy in Polycythemia Vera (CYTO-PV) study, 
we compared the efficacy of conventional treat-
ment (phlebotomy, hydroxyurea, or both) aimed 
at maintaining the recommended hematocrit 
target of less than 45%, as compared with a 
level of 45 to 50%, for the prevention of throm-
botic events in patients with polycythemia vera.
Me thods
Eligibility Criteria
The study design has been described in detail 
previously.10 Adults with a diagnosis of polycy-
themia vera according to World Health Organi-
zation (WHO) 2008 diagnostic criteria, including 
the presence of cells carrying a JAK2 V617F or 
exon 12 mutation, were eligible to participate in 
the study. Patients with the following character-
istics were not eligible: substantial liver disease 
(alanine aminotransferase or aspartate amino-
transferase level, >2.5 times the upper limit of 
the normal range) or renal disease (creatinine 
level, >2 mg per deciliter [177 μmol per liter]); a 
history of active substance or alcohol abuse with-
in the past year; pregnancy, lactation, or lack of 
an accepted method of contraception for women 
of childbearing age; the presence of any life-
threatening condition or any disease that is like-
ly to substantially shorten life expectancy; previ-
ous side effects while receiving hydroxyurea; or 
any condition that in the opinion of the investi-
gator could result in poor adherence to the pro-
tocol. All patients provided written informed 
consent.
Study Design
From May 2008 to February 2012, we enrolled 
365 patients at 26 centers in Italy. At enrollment, 
the patients were stratified according to the pres-
ence or absence of a history of thrombosis, age 
group (<65 years or ≥65 years), and referring 
medical center. We randomly assigned the pa-
tients in a 1:1 ratio to undergo phlebotomy, re-
ceive hydroxyurea, or both, with one group re-
ceiving more aggressive therapy for a hematocrit 
target of less than 45% (low-hematocrit group) 
and the other group receiving less aggressive 
therapy for a hematocrit target of 45 to 50% 
(high-hematocrit group). The protocol dictated 
that the hematocrit target to which the patient 
was assigned had to be maintained during the 
course of the study. The choice of the best thera-
peutic approach was left to the investigator (phle-
botomy, cytoreductive drugs, or both), although 
a recommendation was made to use hydroxyurea 
as the drug of choice in patients at high risk for 
thrombosis (age, >65 years; or previous throm-
bosis) or in those with progressive thrombocyto-
sis or splenomegaly. Other drugs were permitted 
according to the physician’s judgment.
Phlebotomy was initially performed by re-
moving 250 to 500 ml of blood every other day 
or twice a week until the hematocrit target was 
reached. Hydroxyurea was initially administered 
at a dose of 0.5 to 1.0 g daily. In the first 6 
months of the study, patients receiving hydroxy-
urea were followed with weekly blood counts to 
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adjust the dose to achieve a platelet count of less 
than 400,000 per cubic millimeter. The hydroxy-
urea dose was reduced in cases of a leukocyte 
count of less than 3500 per cubic millimeter. 
Low-dose aspirin was to be administered to all 
patients who had no contraindications. Any 
other treatment for controlling additional car-
diovascular risk factors (e.g., diabetes, hyperten-
sion, and hyperlipidemia) was encouraged. If the 
medication was discontinued or changed, the 
reason was recorded in case-report forms. All 
patients were followed until study completion. A 
permanent discontinuation or change in the 
randomized hematocrit target was considered 
only in the best interest of the patient, but the 
schedule of planned follow-up visits according 
to study protocol did not change.
Information recorded at each visit included 
the occurrence of thrombotic or hemorrhagic 
events, hematologic transformation, or onset of 
solid tumors. Follow-up forms requesting details 
of diagnoses of the primary end point were com-
pleted every 6 months.
The trial was approved by the ethics commit-
tees at each participating hospital, and standard 
operating procedures compliant with interna-
tional guidelines11 were adopted. The protocol, 
including the statistical analysis plan, is avail-
able with the full text of this article at NEJM.org.
Study End Points
The primary composite end point was the time 
until death from cardiovascular causes or throm-
botic events (stroke, acute coronary syndrome, 
transient ischemic attack, pulmonary embolism, 
abdominal thrombosis, deep-vein thrombosis, or 
peripheral arterial thrombosis), as defined by 
the International Classification of Diseases, 9th Revision, 
Clinical Modification. An end-point committee ad-
judicated causes of death and events that were 
included in the primary end point on the basis of 
prespecified definitions and procedures. (The def-
initions are provided in the table in the Supple-
mentary Appendix, available at NEJM.org.)
The secondary end point was the total rate of 
cardiovascular events, defined as the primary 
end point plus superficial-vein thrombosis. Ad-
ditional end points were incidence of cancer, 
progression to myelofibrosis, myelodysplasia or 
leukemic transformation, total and nonfatal 
major hemorrhage (any hemorrhage requiring 
transfusion, hospitalization, or both), and minor 
bleeding.
Safety
Serious and relevant adverse events were record-
ed according to the classification code of the 
Medical Dictionary for Regulatory Activities and were 
graded according to the National Cancer Institute 
Common Toxicity Criteria (http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/
docs/ctcaev3.pdf).
Study Oversight
This investigator-initiated clinical trial was spon-
sored mainly by the Italian Medicines Agency 
(AIFA). Medical therapy was provided as part of 
the standard care of the National Health System.
The steering committee was solely responsible 
for the planning and coordination of the study, 
the analysis and interpretation of the data, the 
preparation of the manuscript, and making the 
decision to submit the manuscript for publica-
tion. No agreements concerning confidentiality 
of the data were stipulated between the funder 
and the authors. The study was designed by the 
lead and senior authors. Data collection was per-
formed at Consorzio Mario Negri Sud through a 
Web-based database-management system and 
supervised by the study coordinator. Study inves-
tigators recruited and followed the patients dur-
ing the course of the study. The analyses were 
performed by the lead author and the statisti-
cians at Consorzio Mario Negri Sud. The manu-
script was drafted by the lead author, reviewed by 
the members of the steering committee, and cir-
culated for comments among the main authors. 
No one who is not an author contributed to the 
manuscript. The authors vouch for the accuracy 
and completeness of the data and the fidelity of 
study conduct and analysis to the study protocol.10
Statistical Analysis
We determined that 1000 patients would need to 
be enrolled and followed for 5 years in order to 
provide a power of 80% to detect a relative risk 
reduction of 30% in the low-hematocrit group on 
the basis of an event rate in the high-hematocrit 
group of 5% per year7,12,13 and an alpha level of 
0.05. After 4 years of recruitment, 365 patients 
had been enrolled in the study. Because of a pro-
gressive decline in the rate of recruitment as well 
as competition with trials testing the efficacy of 
new JAK2-inhibiting drugs, the steering commit-
tee decided to close the study in 2012 and to ana-
lyze the study results, since the planned recruit-
ment target was unlikely to be reached.
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Baseline characteristics of the study patients 
were compared with the use of the chi-square 
test or Fisher’s exact test for categorical variables 
and the t-test or nonparametric test for continu-
ous variables. We used the Kaplan–Meier meth-
od to analyze survival and used the log-rank test 
to assess differences between survival curves. 
Unadjusted hazard ratios and 95% confidence 
intervals were calculated by fitting Cox propor-
tional-hazards models. The assumption of pro-
portional hazards for the two study groups was 
checked by means of log-minus-log survival 
plots and the time-dependent covariate test. In-
teraction of the experimental treatments with 
the prespecified subgroups was assessed by fit-
ting a Cox model with one term representing the 
treatment group, one representing the covariate 
of interest, and an interaction term. The follow-
ing subgroups were considered: pharmacologic 
versus nonpharmacologic cytoreductive therapy; 
sex; median age; previous thrombosis versus no 
previous thrombosis; low-risk disease versus 
high-risk disease; baseline platelet and white-
cell counts (above or below the median value); 
the presence or absence of splenomegaly, diabe-
tes, or hypertension; and the use versus nonuse 
of aspirin or other anticoagulant drugs.
All reported P values are two-sided. All analy-
ses were performed with the use of SAS soft-
ware, version 9.2.
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Low Hematocrit
(N = 182)
High Hematocrit  
(N = 183)
All Patients
(N = 365)
Age at recruitment — yr 64.8±12.1 64.3±12.2 64.5±12.2
Male sex — no. (%) 116 (63.7) 111 (60.7) 227 (62.2)
Time from diagnosis to enrollment
Mean — yr 4.5±5.6 4.0±5.3 4.3±5.4
0–2 yr — no. (%) 88 (48.4)  92 (50.3) 180 (49.3)
Hematologic values
Hemoglobin — g/dl 15.2±1.7 15.4±1.7 15.3±1.7
Hematocrit — % 47.2±5.1 47.5±4.4 47.4±4.7
Platelet count — per mm3 390,000 421,000 406,000
Red-cell count — per mm3 5,800,000 5,700,000 5,700,000
White-cell count — per mm3 9,000 9,700 9,300
Previous thrombotic events — no. (%) 52 (28.6)  53 (29.0) 105 (28.8)
Arterial 29 (15.9)  34 (18.6)  63 (17.3)
Venous 25 (13.7)  20 (10.9)  45 (12.3)
Previous hemorrhagic events — no. (%) 6 (3.3) 12 (6.6) 18 (4.9)
Mutational status — no. (%)†
JAK2 V617F 177 (97.3) 178 (97.3) 355 (97.3)
JAK2 exon 12 3 (1.6)  3 (1.6)  6 (1.6)
Treatments for cardiovascular risk factors — no. (%)
Hypocholesterolemic medication 23 (12.6)  24 (13.1)  47 (12.9)
Antidiabetic medication 9 (4.9)  8 (4.4) 17 (4.7)
Antihypertensive medication 93 (51.1)  83 (45.4) 176 (48.2)
Antithrombotic treatment — no. (%)
Antiplatelet agent 151 (83.0) 157 (85.8) 308 (84.4)
Aspirin 139 (76.4) 140 (76.5) 279 (76.4)
Anti–vitamin K agent 25 (13.7)  24 (13.1)  49 (13.4)
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R esult s
Patients
Of the 365 patients in the study, 182 were ran-
domly assigned to the low-hematocrit group and 
183 to the high-hematocrit group. The intention-
to-treat analysis included all 365 patients (Fig. S1 
in the Supplementary Appendix). Baseline char-
acteristics were well balanced between the two 
groups (Table 1). Approximately half the patients 
had received an initial diagnosis within 2 years 
before randomization. All patients carried the 
JAK2 V617F mutation except for 10, of whom 5 
carried a JAK2 exon 12 mutation and 5 had an 
unknown mutation status; enrollment of the lat-
ter 5 patients constituted a deviation from the 
protocol.
Of the 365 patients, 245 (67.1%) were at high 
risk because of an age of 65 years or older or 
previous thrombosis; 91 patients (24.9%) had had 
thrombotic events more than 12 months before 
undergoing randomization, and 63 of these 
events (60.0%) were arterial thromboses. Fifty-
five percent of the patients had hypertension and 
17% had hypercholesterolemia. The most com-
mon therapies at enrollment were antiplatelet 
agents (84.4%) — most frequently aspirin (76.4%) 
— phlebotomy (68.0%), hydroxyurea (52.6%), 
and antihypertensive medication (48.2%).
Changes in Type of Therapy
Patients were followed for a mean (±SD) of 
28.9±10.9 months (range, 1.5 to 48.1). We as-
sessed the change of therapy from baseline to the 
6-month follow-up visit in the two study groups. 
In the low-hematocrit group, phlebotomy was 
initiated in 14 patients (7.7%) and hydroxyurea 
treatment in 10 patients (5.5%); in previously 
treated patients, the mean dose of hydroxyurea 
increased by 5.5% (from 763 to 806 mg daily) and 
the number of phlebotomies increased by 36.4% 
(average per patient, 2.2 to 3.0 during a 6-month 
period). In the high-hematocrit group, 52 pa-
tients (28.4%) stopped phlebotomy and 8 (4.4%) 
stopped hydroxyurea treatment; in patients treat-
ed in both visits, the mean dose of hydroxyurea 
decreased by 9.8% (from 783 to 706 mg daily) 
and the number of phlebotomies increased by 
15.8% (average per patient, 1.9 to 2.2 during a 
6-month period).
Table 1. (Continued.)
Characteristic
Low Hematocrit
(N = 182)
High Hematocrit  
(N = 183)
All Patients
(N = 365)
Cytoreductive treatment
Use of phlebotomy
Patients — no. (%) 127 (69.8) 121 (66.1) 248 (68.0)
Procedures in past 6 mo — no.
Median 2.0 2.0 2.0
Interquartile range 1.0–3.0 1.0–2.5 1.0–2.5
Use of hydroxyurea
Patients — no. (%) 98 (53.8) 94 (51.4) 192 (52.6)
Dose — mg/day
Median 732 750 750
Interquartile range 500–1000 500–1000 500–1000
Use of other drugs — no. of patients (%)
Pipobroman 9 (4.9) 8 (4.4) 17 (4.7)
Interferon 6 (3.3) 1 (0.5)  7 (1.9)
Busulfan 1 (0.5) 1 (0.5)  2 (0.5)
* Plus–minus values are means ±SD. There was no significant difference between the two groups.
† One patient in the low-hematocrit group had both JAK2 V617F and exon 12 mutations.
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Hematocrit, White-Cell Count, and Platelet 
Count
The mean (±SD) hematocrit at baseline was simi-
lar in the low-hematocrit group and high-hema-
tocrit group (47.2±5.1% vs. 47.5±4.4%). During 
the study period, the median hematocrit level 
that was maintained in the low-hematocrit group 
was 44.4%, as compared with 47.5% in the high-
hematocrit group (Fig. 1A). Approximately three 
of four patients in each group were correctly 
maintained in the randomly assigned hematocrit 
target range during the study. The white-cell 
count remained significantly higher in the high-
hematocrit group than in the low-hematocrit 
group (P<0.001) (Fig. 1B). No significant between-
group difference was noted in the platelet count 
(Fig. 1C).
Primary and Secondary End Points
After a median of 31 months of follow-up, the 
primary end point was recorded in 5 of 182 pa-
tients in the low-hematocrit group (2.7%) and 18 
of 183 patients in the high-hematocrit group 
(9.8%) (hazard ratio in the high-hematocrit 
group, 3.91; 95% confidence interval [CI], 1.45 to 
10.53; P = 0.007) (Fig. 2A). The incidence of death 
from cardiovascular causes or major thrombosis 
was 1.1 per 100 person-years in the low-hemato-
crit group and 4.4 per 100 person-years in the 
high-hematocrit group. Total cardiovascular 
events occurred in 4.4% of patients in the low-
hematocrit group and 10.9% of those in the high-
hematocrit group (hazard ratio, 2.69; 95% CI, 
1.19 to 6.12; P = 0.02) (Fig. 2B). No significant 
interaction was found for the effect of study-group 
assignment in the subgroup analyses (Fig. 3).
Progression to myelofibrosis, myelodysplasia 
or leukemic transformation, and bleeding were 
observed in six, two, and two patients respec-
tively, in the low-hematocrit group, as compared 
with two, one, and five patients, respectively, in 
the high-hematocrit group (Table 2). Twelve 
solid tumors were observed during the study: 
seven in the low-hematocrit group and five in 
the high-hematocrit group. Two other hemato-
logic cancers occurred, one in each study group.
Adverse Events
By the end of the study, 4 patients (2.2%) in the 
low-hematocrit group and 5 (2.7%) in the high-
hematocrit group had stopped or changed their 
assigned treatment, mainly because of progres-
sion of disease. Thirty-nine adverse events were 
reported in 35 patients, 25 of which occurred in 
the low-hematocrit group and 14 in the high-
hematocrit group (see the Materials section in the 
Supplementary Appendix). One serious adverse 
event occurred during the study in the low-hema-
tocrit group (one bone fracture) and three in the 
high-hematocrit group (one case of diarrhea, one 
case of dizziness, and one case of bronchitis).
Discussion
The results of this study in patients with polycy-
themia vera who were receiving conventional 
treatment (including phlebotomy, hydroxyurea, 
or both) show that maintaining a hematocrit tar-
get of 45 to 50% was associated with four times 
the rate of death from cardiovascular causes or 
major thrombosis, as was maintaining a hemato-
crit target of less than 45%. The incidence of the 
primary end point was 1.1 events per 100 patient-
years in the low-hematocrit group, as compared 
with 4.4 events per 100 patient-years in the high-
hematocrit group. Rates of deep-vein thrombosis 
and cerebral vascular events including strokes 
and transient ischemic attacks were increased in 
the high-hematocrit group, confirming the high-
er incidence of thrombosis observed in the Euro-
pean Collaboration on Low-Dose Aspirin in Poly-
cythemia Vera (ECLAP) study.7,14 On the other 
hand, slight, nonsignificant increases in rates of 
hematologic progression and solid cancer were 
observed in the low-hematocrit group. However, 
the follow-up period was too short to make infer-
ence about transformation rates into myelofibro-
sis, myelodysplasia, or leukemia in the two study 
groups.
This significant benefit in the low-hematocrit 
group was largely unanticipated on the basis of 
Figure 1 (facing page). Hematocrit (HCT) and White-Cell 
and Platelet Counts during the Study.
Patients in the low-HCT group were assigned to receive 
more intensive therapy, in which the goal was to reach 
and maintain an HCT target of less than 45%. Patients 
in the high-hematocrit group were assigned to receive 
less intensive therapy, in which the goal was to reach 
and maintain an HCT target of 45 to 50%. Shown are 
the 25th, 50th (median), and 75th percentiles for hema-
tocrit (Panel A), white-cell count (Panel B), and platelet 
count (Panel C) at various time points in the two study 
groups.
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previous reports and contrasts with findings of 
the post hoc, hypothesis-generating analyses of 
the ECLAP study and the Polycythemia Vera 
Study Group (PVSG-01).7-9 However, post hoc 
multivariate analyses can adjust only for con-
founding, do not fully adjust results in case of 
measurement error, are usually not powered to 
test for interaction, cannot account for unmea-
sured factors, and can be influenced by the indi-
cation bias. Conversely, our findings are in 
agreement with the original retrospective obser-
vation published more than 30 years ago by 
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Figure 2. Kaplan–Meier Curves for the Primary End Point and Total Cardiovascular Events.
Shown are the time to the primary end point (death from cardiovascular causes or thrombotic events) (Panel A) and 
total cardiovascular events, defined as the primary end point plus superficial-vein thrombosis, a secondary end point 
(Panel B), among patients with a high or low hematocrit (HCT) target. The inset graphs show a more detailed ver-
sion of the overall graphs down to a probability of 0.7. The hazard ratios were calculated with the use of a Cox pro-
portional-hazards model.
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Pearson and Wetherley-Mein,15 which led to the 
adoption of current guidelines (though in the 
absence of randomized clinical trials).1
Notably, our results do not address whether 
even lower hematocrit thresholds would be even 
better. The benefit of intensive hematocrit reduc-
tion was consistent in the examined subgroups, 
and no significant heterogeneity of results was 
found according to age, previous thrombosis, 
platelet or white-cell counts, splenomegaly, pre-
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Figure 3. Risk of the Primary End Point in Prespecified Subgroups.
Among prespecified subgroups of patients with a high or low hematocrit (HCT), hazard ratios are indicated by solid squares. Horizontal 
lines represent the 95% confidence intervals as calculated by a Cox proportional-hazards model, with arrows indicating that the upper or 
lower limit is not shown. P values for hazard ratios were calculated with the use of Cox proportional-hazards models. Interaction of the 
study treatments with the prespecified subgroups was assessed by fitting a Cox model with one term representing the treatment group, 
one representing the covariate of interest, and an interaction term; P values for the interaction term are shown. A double-logarithmic 
scale is shown on the x axis. One patient in the low-HCT group had missing values for laboratory measures at baseline. For some sub-
groups, values do not sum to totals because categories with very low frequencies were excluded from the analysis.
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vious cytoreductive treatment, or antiplatelet or 
anticoagulant medication. Similar results were 
found in men and women. An association be-
tween increased blood viscosity and both arte-
rial and venous thrombosis has been reported in 
various epidemiologic studies in general popula-
tions and in patients with nonclonal erythrocy-
tosis, such as polycythemia of high altitude, 
Table 2. Primary and Secondary End Points.*
End Point
Low Hematocrit
(N = 182)
High Hematocrit 
(N = 183)
All Patients
(N = 365)
Hazard Ratio
(95% CI) P Value
number (percent)
Primary end point† 5 (2.7) 18 (9.8) 23 (6.3) 3.91  
(1.45–10.53)
 0.007
Total cardiovascular events‡ 8 (4.4)  20 (10.9) 28 (7.7) 2.69
(1.19–6.12)
0.02
Death
All patients 3 (1.6)  6 (3.3)  9 (2.5) 2.15
(0.54–8.62)
0.28
Cardiovascular causes 0  4 (2.2)  4 (1.1) NA
Myocardial infarction 0  1 (0.5)  1 (0.3) NA
Stroke 0  2 (1.1)  2 (0.5) NA
Pulmonary embolism 0  1 (0.5)  1 (0.3) NA
Cancer 2 (1.1)  1 (0.5)  3 (0.8) 0.55
(0.05–6.02)
0.62
Nonfatal events
Myocardial infarction 3 (1.6) 0  3 (0.8) NA
Stroke 0  4 (2.2)  4 (1.1) NA
Peripheral arterial thrombosis 0  3 (1.6)  3 (0.8) NA
Deep-vein thrombosis 1 (0.5)  4 (2.2)  5 (1.4) 4.11
(0.46–36.74)
0.21
Pulmonary embolism 0  1 (0.5)  1 (0.3) NA
Transient ischemic attack 1 (0.5)  4 (2.2)  5 (1.4) 4.24
(0.47–37.97)
0.20
Superficial thrombophlebitis 4 (2.2)  2 (1.1)  6 (1.6) 0.51
(0.09–2.79)
0.44
Bleeding 2 (1.1)  5 (2.7)  7 (1.9) 2.53
(0.49–13.06)
0.27
Hematologic progression or cancer
Myelofibrosis 6 (3.3)  2 (1.1)  8 (2.2) 0.34
(0.07–1.67)
0.18
Myelodysplasia or acute leukemia 2 (1.1)  1 (0.5)  3 (0.8) 0.52
(0.05–5.71)
0.59
Other hematologic cancer 1 (0.5)  1 (0.5)  2 (0.5) 1.02
(0.06–16.23)
0.99
Solid cancer 7 (3.8)  5 (2.7) 12 (3.3) 0.74
(0.23–2.33)
0.60
* NA denotes not applicable.
† The primary end point was death from cardiovascular causes or thrombotic events (stroke, acute coronary syndrome, 
transient ischemic attack, pulmonary embolism, abdominal thrombosis, deep-vein thrombosis, or peripheral arterial 
thrombosis). The incidence of the primary end point was 1.1 per 100 person-years in the low-hematocrit group, as 
compared with 4.4 per 100 person-years in the high-hematocrit group.
‡ Total cardiovascular events consisted of the primary end point plus superficial-vein thrombosis. The incidence of total 
cardiovascular events was 1.9 per 100 person-years in the low-hematocrit group, as compared with 5.0 per 100 person-
years in the high-hematocrit group.
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erythropoietin receptor mutations, Chuvash poly-
cythemia, hemoglobin mutants with high oxygen 
affinity, and 2,3-bisphosphoglycerate deficiency. 
In these conditions, which are all characterized 
by an elevated hematocrit with normal leukocyte 
and platelet counts, rates of thrombotic compli-
cations are higher than in controls but far below 
those seen in patients with polycythemia vera.16,17 
Among patients with polycythemia vera, in addi-
tion to the hematocrit levels, other components 
of the myeloproliferative process may be associ-
ated with thrombosis, including quantitative and 
qualitative defects of platelets and leukocytes, as 
shown also in essential thrombocythemia.18-20
The hematocrit is not a perfect therapeutic 
guide in patients with polycythemia vera because 
it cannot be used as an accurate surrogate for the 
red-cell mass (e.g., increases in plasma volume 
could mask the degree of increase in red-cell 
mass).1 In our study, patients in the high-hema-
tocrit group had significantly higher leukocyte 
counts than did those in the low-hematocrit 
group, but platelet counts were similar in the 
two groups. Thus, in the high-hematocrit group, 
in which the use of hydroxyurea was less frequent 
than in the low-hematocrit group, the persis-
tence of leukocytosis could have contributed to 
an excess of thrombosis. This finding cannot be 
generalized to cytoreductive drugs other than 
hydroxyurea. The issue of the potential long-
term leukemogenesis from hydroxyurea has been 
raised as a potential limitation to its wider use. 
However, hydroxyurea is a standard therapy in 
high-risk patients with polycythemia vera, and the 
leukemogenic risk of hydroxyurea in the long 
term is low, though the issue is controversial.12,21
Some limitations of our study should be ac-
knowledged. A significant result was obtained 
even though the study was closed before its 
planned end. Nevertheless, a higher-than-expected 
benefit was noted in the low-hematocrit group. 
The main study findings were consistent with 
those obtained in the prespecified subgroups. 
Not unexpectedly for a pragmatic trial in clinical 
practice that tested the efficacy of different 
therapeutic targets,22,23 not all patients were 
maintained at the assigned hematocrit target. 
However, the intention-to-treat analysis showed 
positive results despite the variability.
In conclusion, among patients with polycy-
themia vera, maintaining a hematocrit target 
of less than 45%, as compared with a target of 
45 to 50%, was associated with a significantly 
lower rate of thrombotic complications without 
an increase in serious treatment complications.
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